TREM2 and nonpapillary renal cell carcinoma: Here, we show that TREM2 is elevated in the TME myeloid cells (Supplementary Fig. 2g–i), pointing to the potential as a prognostic marker in ccRCC and as a biomarker that could identify patients that would benefit from checkpoint blockade immunotherapy.